Similar articles

• Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.

  Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, Tachibana K, Isa S, Takada M, Kurata T. Tsujino K, et al. J Thorac Oncol. 2009 Aug;4(8):994-1001. doi: 10.1097/JTO.0b013e3181a94a2f. J Thorac Oncol. 2009. PMID: 19633474
• [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].

  Longo F, Giovanni M. Longo F, et al. Tumori. 2006 Sep-Oct;92(5):suppl 13-22. Tumori. 2006. PMID: 17168450 Review. Italian. No abstract available.
• [New era in cancer therapy. Gefitinib: small molecule--strong action].

  Arnheim K. Arnheim K. MMW Fortschr Med. 2004 Nov 18;146(47):70-1. MMW Fortschr Med. 2004. PMID: 15624666 German. No abstract available.
• Network meta-analysis: importance of appropriate trial selection.

  Edwards SJ, Borrill J. Edwards SJ, et al. Value Health. 2010 Aug;13(5):681-2; author reply 683. doi: 10.1111/j.1524-4733.2010.00715.x. Epub 2010 Mar 22. Value Health. 2010. PMID: 20345543 No abstract available.
• The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

  Comis RL. Comis RL. Oncologist. 2005 Aug;10(7):467-70. doi: 10.1634/theoncologist.10-7-467. Oncologist. 2005. PMID: 16079313 Review. No abstract available.